Insights & Resources

Learn how the SEC custody rule and surprise examinations apply to RIAs and key compliance basics in Weaver’s RIA Surprise Examinations series.

An executive order could allow 401(k)s to invest in private equity and other alternatives. Explore the opportunities, challenges and compliance needs.

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

The SEC’s new guidance on Rule 506(c) allows accredited investors making high-minimum investments to verify their status through self-certification.

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The credit analysis function is a key element of fixed income investment management, assessing the creditworthiness of issuers and ensuring sound investment decisions.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.